全文获取类型
收费全文 | 1219584篇 |
免费 | 83454篇 |
国内免费 | 1959篇 |
专业分类
耳鼻咽喉 | 16631篇 |
儿科学 | 38184篇 |
妇产科学 | 30984篇 |
基础医学 | 172764篇 |
口腔科学 | 32767篇 |
临床医学 | 109613篇 |
内科学 | 234530篇 |
皮肤病学 | 27379篇 |
神经病学 | 95047篇 |
特种医学 | 49316篇 |
外国民族医学 | 215篇 |
外科学 | 186251篇 |
综合类 | 23523篇 |
现状与发展 | 1篇 |
一般理论 | 375篇 |
预防医学 | 85694篇 |
眼科学 | 27569篇 |
药学 | 95551篇 |
7篇 | |
中国医学 | 3019篇 |
肿瘤学 | 75577篇 |
出版年
2021年 | 10586篇 |
2019年 | 10597篇 |
2018年 | 14537篇 |
2017年 | 11420篇 |
2016年 | 12961篇 |
2015年 | 14499篇 |
2014年 | 19908篇 |
2013年 | 28517篇 |
2012年 | 39960篇 |
2011年 | 42363篇 |
2010年 | 24782篇 |
2009年 | 23367篇 |
2008年 | 38887篇 |
2007年 | 41399篇 |
2006年 | 42000篇 |
2005年 | 40355篇 |
2004年 | 38299篇 |
2003年 | 36474篇 |
2002年 | 35137篇 |
2001年 | 62000篇 |
2000年 | 63148篇 |
1999年 | 52862篇 |
1998年 | 14244篇 |
1997年 | 12447篇 |
1996年 | 12258篇 |
1995年 | 11514篇 |
1994年 | 10405篇 |
1993年 | 9800篇 |
1992年 | 39020篇 |
1991年 | 37388篇 |
1990年 | 36723篇 |
1989年 | 35221篇 |
1988年 | 31748篇 |
1987年 | 30814篇 |
1986年 | 29062篇 |
1985年 | 27280篇 |
1984年 | 20056篇 |
1983年 | 16901篇 |
1982年 | 9732篇 |
1979年 | 17651篇 |
1978年 | 12059篇 |
1977年 | 10756篇 |
1976年 | 9333篇 |
1975年 | 10496篇 |
1974年 | 12139篇 |
1973年 | 11732篇 |
1972年 | 11151篇 |
1971年 | 10397篇 |
1970年 | 9547篇 |
1969年 | 9174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.
Andrology was included as a further subject for continuing education in the Model Ordinance on Continuing Education at the 106th German Physicians’ Meeting in Cologne in 2003. In addition to fertility disorders, this discipline comprises medical care for men with fertility disorders, erectile dysfunction, disorders of libido, ejaculation, and coitus, various forms of hypogonadism, and delayed puberty. Furthermore, this field also covers questions concerning male contraception, gynecomastia, and male senescence. Diagnostic procedures in andrology require close interdisciplinary cooperation with practitioners of gynecology, human genetics, and psychosomatic medicine. It includes medical history, clinical examination, and laboratory analyses. Except to confirm azoospermia, it is not possible to make a definitive prognosis for fertility based on semen analysis. Functional tests allow a better assessment of the spermatozoa’s fertility since 25–30% of men desiring a child exhibit reduced spermatozoal functions, which cannot be verified on routine semen analysis. 相似文献
952.
953.
954.
A novel balanced SSFP technique for the separation or suppression of different resonance frequencies (e.g., fat suppression) is presented. The method is based on applying two alternating and different repetition times, TR(1) and TR(2). This RF scheme manipulates the sensitivity of balanced SSFP to off-resonance effects by a modification of the frequency response profile. Starting from a general approach, an optimally broadened stopband within the frequency response function is designed. This is achieved with a TR(2) being one third of TR(1) and an RF-pulse phase increment of 90 degrees . With this approach TR(2) is too short ( approximately 1 ms) to switch imaging gradients and is only used to change the frequency sensitivity. Without a significant change of the spectral position of the stopband, TR(1) can be varied over a range of values ( approximately 2.5-4.5 ms) while TR(2) and phase cycling is kept constant. On-resonance spins show a magnetization behavior similar to balanced SSFP, but with maximal magnetization at flip angles about 10 degrees lower than in balanced SSFP. The total scan time is increased by about 30% compared to conventional balanced SSFP. The new technique was applied on phantoms and volunteers to produce rapid, fat suppressed images. 相似文献
955.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
956.
957.
958.
959.
K. A. Jellinger 《European journal of neurology》2009,16(9):e168-e168
960.